{"id":690,"date":"2026-04-13T04:23:49","date_gmt":"2026-04-13T04:23:49","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=690"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"lucirevu-revumenib-110mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/zh\/product\/lucirevu-revumenib-110mgx30-tablets\/","title":{"rendered":"\u745e\u7ef4\u7f8e\u5c3c110mg"},"content":{"rendered":"<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">HIGHLIGHTS OF PRESCRIBING INFORMATION<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">These highlights do not include all the information needed to use LuciRevu safely and effectively. See full prescribing information for LuciRevu.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"color: rgb(88, 88, 88); font-size: 17px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">INDICATIONS AND USAGE<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">LuciRevu is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">DOSAGE AND ADMINISTRATION<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">\u2022 Select patients for treatment with LuciRevu based on the presence of a KMT2A translocation.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;Administer LuciRevu orally twice daily fasted or with a low-fat meal at approximately the same time each day.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;The recommended dosage of LuciRevu varies by patient weight and concomitant use of strong CYP3A4 inhibitors. See Table 1 for the recommended dosage for patients 1 year and older. Do not start LuciRevu until the WBC is reduced to less than 25 Gi\/L. Continue LuciRevu until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.<\/span><\/span><\/p>\n<table border=\"1\" style=\"border: none;\">\n<tbody>\n<tr>\n<td width=\"174\" valign=\"top\" style=\"padding: 0px 7px; border-color: windowtext; width: 140px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">Patient Weight<\/span><\/p>\n<\/td>\n<td width=\"283\" valign=\"top\" style=\"padding: 0px 7px; border-color: windowtext; width: 227px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;Without Strong CYP3A4 Inhibitors<\/span><\/p>\n<\/td>\n<td width=\"252\" valign=\"top\" style=\"padding: 0px 7px; border-color: windowtext; width: 202px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">With Strong CYP3A4 Inhibitors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"174\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 140px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">40 kg or more<\/span><\/p>\n<\/td>\n<td width=\"283\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 227px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">270 mg orally twice daily<\/span><\/p>\n<\/td>\n<td width=\"252\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 202px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">160 mg orally twice daily<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"174\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 140px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">Less than 40 kg<\/span><\/p>\n<\/td>\n<td width=\"283\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 227px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">160 mg\/m<\/span><sup><span style=\"font-size: 14px; vertical-align: super;\">2<\/span><\/sup><span style=\"font-size: 14px;\">&nbsp;orally twice daily<\/span><\/span><\/p>\n<\/td>\n<td width=\"252\" valign=\"top\" style=\"padding: 0px 7px; border-top: none; border-right-color: windowtext; border-bottom-color: windowtext; border-left-color: windowtext; width: 202px;\">\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">95 mg\/m<\/span><sup><span style=\"font-size: 14px; vertical-align: super;\">2<\/span><\/sup><span style=\"font-size: 14px;\">&nbsp;orally twice daily<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;See Full Prescribing Information for dosage modifications, and administration instructions.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">DOSAGE FORMS AND STRENGTHS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">Tablets:&nbsp;<\/span><span style=\"font-size: 14px;\">110mg\u00d730 tablets\/bottle<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">CONTRAINDICATIONS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">None<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">WARNINGS AND PRECAUTIONS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;QTc Interval Prolongation: Monitor electrocardiograms and electrolytes. Correct hypokalemia and hypomagnesemia prior to and during treatment. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue LuciRevu.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">ADVERSE REACTIONS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">The most common adverse reactions (\u2265 20%) including laboratory&nbsp;<\/span><span style=\"font-size: 14px;\">abnormalities, are hemorrhage, nausea, phosphate increased, musculoskeletal pain, infection, aspartate aminotransferase increased, febrile neutropenia, alanine aminotransferase increased, parathyroid hormone intact increased, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, phosphate decreased, triglycerides increased, potassium decreased, decreased appetite, constipation, edema, viral infection, fatigue, and alkaline phosphatase increased.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">DRUG INTERACTIONS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Strong CYP3A4 Inhibitors: Reduce the LuciRevu dose.<\/span><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022&nbsp;<\/span><span style=\"font-size: 14px;\">Strong or moderate CYP3A4 Inducers: Avoid concomitant use with LuciRevu.<\/span><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022&nbsp;<\/span><span style=\"font-size: 14px;\">QTc Prolonging Drugs: Avoid concomitant use with LuciRevu. If concomitant use is unavoidable, monitor patients more frequently for QTc interval prolongation.<\/span><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">USE IN SPECIFIC POPULATIONS<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">\u2022 Lactation: Advise not to breastfeed<\/span><span style=\"font-size: 14px;\">.<\/span><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size: 14px; font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><strong><span style=\"font-size: 14px;\">Storage<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-family: \u5fae\u8f6f\u96c5\u9ed1, &quot;Microsoft YaHei&quot;;\"><span style=\"font-size: 14px;\">Store at 20<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">C to 25<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">C (68<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">F to 77<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">F), excursions permitted between 15<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">C and 30<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">C (59<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">F and 86<\/span><span style=\"font-size: 14px;\">\u00b0<\/span><span style=\"font-size: 14px;\">F) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/span><\/p>\n<p><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciRevu is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.<\/p>","protected":false},"featured_media":2074,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[21],"product_tag":[],"class_list":["post-690","product","type-product","status-publish","has-post-thumbnail","product_cat-blood-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product\/690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/comments?post=690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/media\/2074"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/media?parent=690"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_brand?post=690"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_cat?post=690"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_tag?post=690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}